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Major trauma is associated with significant blood loss due to trauma-related severity 
of injuries and trauma-related coagulopathy. Acute coagulopathy in trauma patients 
is frequent and has been associated with worse clinical outcome 1-2. In this issue of 
the Journal, Fries and Martini review the mechanisms of trauma-related coagulopathy 
and the central role of fibrinogen in the treatment of this entity 3. This is a very timely 
issue since the understanding of the coagulopathy of trauma and shock has indeed 
increased tremendously in the recent years. In addition, fibrinogen is increasingly 
viewed as the coagulation factor that in most massive bleeding cases is becoming 
critically low first 1. 
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Acute traumatic coagulopathy has traditionally been explained by the paradigm of an 
acquired disorder in the coagulation system through loss or impaired function of 
coagulation proteases and platelets. However, severe trauma leads to massive 
haemorrhage with activation and subsequent exhaustion of the coagulation system. 
Dilution from fluid resuscitation results in an additional relative deficiency of 
coagulation factors and platelets. Finally, physical factors such as acidaemia and 
hypothermia further compromise coagulation proteases and platelet function, 
worsening the evolving coagulopathy. 
Recent studies have shown that nearly 25% of trauma patients present with a 
clinically significant and outcome relevant coagulopathy upon arrival in the 
emergency department 4. Interestingly, this early coagulopathy occurred prior to any 
significant consumption or fluid administration and in absence of a relevant 
acidaemia or hypothermia. Therefore, it has been postulated that the early 
coagulopathy after trauma be physiologically and mechanistically distinct from the 
above-mentioned coagulopathy. This acute coagulopathy of trauma, also called 
endogenous acute coagulopathy (EAC) 5 or acute coagulopathy of trauma and shock 
(ACoTS) 6 is driven by the combinations of tissue trauma and shock with systemic 
hypoperfusion. Thereby, the anticoagulant thrombomodulin protein C pathway is 
overtly getting activated, resulting in reduced pro-coagulatory potential and increased 
fibrinolytic activity 7-8. Once protein C is being activated through a thrombin-
thrombomodulin dependent reaction, activated protein C (aPC) exerts its profound 
anticoagulant effects by irreversibly inactivating factors Va and VIIIa. In addition to its 
direct inhibition of fibrin formation, aPC resolves already formed clots through its 
derepression of fibrinolysis by direct inhibition of plasminogen activator inhibitor 1 9-10.  
After major trauma, surgeons and anaesthesiologists thus are facing a dual problem: 
There is the physical damage including vascular injury with “surgical” haemorrhage 
and frequently there is a component of coagulopathy with “coagulopathic” bleeding 
(and any combination thereof). The first type of blood loss requires surgical source 
control, the second treatment with pro-coagulatory substances such as labile / 
allogeneic blood products, coagulation factor concentrate and potentially anti-
fibrinolytics. In this situation the physician is facing multiple problems at the same 
time: First, how can he or she analyze the situation within minutes and find out 
whether coagulopathy is present and what the main causes are. Second, what 
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products should be used for treatment, given the hazards, risks, unknowns and costs 
of allogeneic blood products, factor concentrates and anti-fibrinolytics. 
A first option to boost blood coagulation following major trauma is to administer 
“massive transfusion packages” with a fixed, and these days, high fresh frozen 
plasma (FFP) to red blood cell (RBC) ratio, some even including platelets 11. The 
apparent success of such algorithms in improving survival of US Army combat 
victims has been described several times 1. However, there are also studies, in which 
no benefit of a high FFP:RBC on survival was found 12-13, and there is an important 
study showing that the introduction of “massive transfusion packages” resulted in a 
significant reduction of mortality without a change of the 24h FFP:RBC ratio 14. 
Interestingly, in this study FFP (169 min vs. 254 min) and platelets (241 min vs. 418 
min) were administered much earlier following the introduction of “massive 
transfusion packages” 14. There are several important aspects to consider when 
interpreting results of studies showing a benefit of a high FFP:RBC ratio in 
traumatized patients: data are retrospective and primarily refer to young, previously 
healthy male patients with penetrating injuries. In addition, the FFP:RBC ratio usually 
is calculated for the first 24h of treatment. Therefore, there may be a significant 
selection bias in that clinicians allocated most resources including FFP to those 
patients most likely to survive 15. There may also be a survivor bias in that those with 
the worst injury and bleeding died too early to receive a high number of FFP 15-16. In 
addition, FFP transfusion is associated with adverse effects such as increased 
incidence of nosocomial infections 17, multiple organ failure 16, lung injury 15-16 and 
potentially mortality 15, 18. Therefore, although the use of FFP is suggested in massive 
bleeding, neither the recently published AABB guidelines 19 nor the updated 
European guideline on the management of bleeding following major trauma 1 
recommends for transfusion of plasma at a FFP:RBC ratio of 1:3 or more. 
A second option to early and individually optimize blood coagulation following major 
trauma is to assess each trauma patient’s blood coagulation on admission in the 
emergency room and throughout the surgery with point of care viscoelastic 
coagulation monitoring (be it thrombelastography, TEG®, Haemonetics Corp., 
formerly Haemoscope or rotational thrombelastometry, ROTEM®, tem International 
GmbH, formerly Pentapharm) 20. These bed-side devices allow analysing the entire 
blood coagulation within 10-15 min 21 including the detection of (hyper)fibrinolysis 7-8. 
With this information, coagulation can be readily and individually optimized, for 
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example with anti-fibrinolytics and blood coagulation factor concentrates and later, if 
necessary with labile blood products. With such an algorithm the use of RBC, FFP 
and platelets can be significantly reduced 22 and survival of trauma patients 
significantly improved 23. The observed mortality in the study by Schoechl et al. was 
24.4% which was significantly lower than the expected mortality based on the trauma 
injury severity score (TRISS) of 33.7% 23. 
Fibrinogen may indeed be the key element of blood coagulation and the one element 
that is getting critically low first 1. In addition, fibrin polymerization is compromised by 
artificial colloids which are frequently used in the initial resuscitation of trauma 
victims. Interestingly, this form of blood coagulation compromise can be reversed by 
the administration of fibrinogen 24. Therefore, aiming at functional fibrinogen levels as 
assessed by thrombelastometry 22-23, appears reasonable and is also proposed by 
the updated European guideline on the management of bleeding following major 
trauma 1. If such thrombelastometric monitoring is not available, serum fibrinogen 
levels of 1.5 – 2.0 g/L should be aimed at 1. However, clinicians should be aware, 
that in presence of artificial colloids such as hydroxyethyl starch, gelatin or dextran, 
the most often used fibrinogen measurement method, the Clauss methods 
significantly overestimates fibrinogen concentration 25-26. 
An additional benefit of bed-side coagulation monitoring like thrombelastometry is 
speed. If the coagulation status is being analyzed by point of care on arrival in the 
emergency department, the main coagulation problem is known within 15 min. The 
trauma patient can then immediately and specifically be treated according to an 
institutional transfusion algorithm with for example anti-fibrinolytics and coagulation 
factor concentrates. Importantly, guidelines aiming at individually optimizing the 
patient’s coagulation status also avoid excessive pro-coagulatory potential with 
associated thrombotic complications. The time advantage of bed-side coagulation 
monitoring compares very favourable even with the improved times of FFP 
administration (169 min) described in the study by Riskin et al. following the 
introduction of a “massive transfusion package” 14. 
The review by Fries and Martini 3 explaining the mechanisms of coagulopathy of 
trauma and shock and the central role therein of fibrinogen thus is an important 
contribution towards a better understanding of this complex situation and a better 
treatment of trauma victims. Their recommendation to view fibrinogen as a central 
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element of blood coagulation is in phase the updated European guideline on the 
management of bleeding following major trauma 1. The first goal is that all hospitals 
treating trauma patients have an institutional algorithm how to proceed with a heavily 
bleeding major trauma patient. The ultimate goal is to find algorithms allowing early 
individual goal directed coagulation management in trauma patients. To introduce 
such concepts into general medicine, they need to be rigorously tested in large 
prospective randomized trials. 
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